Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of$ 1.28. This compares to loss of $2.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this cancer drug developer would post a loss of$ 1.64 per share when it actually produced a loss of $1.32, delivering a surprise of 19.51%. Over the last four quarters, the ...